非酒精性脂肪性肝病中的血清成纤维细胞生长因子23水平与肝脏脂肪含量：一项基于社区的队列研究
Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort.
作者信息
Cao Weijie, Xu Yiting, Shen Yun, Wang Yufei, Ma Xiaojing, Bao Yuqian
机构信息
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, 200233, People's Republic of China.
出版信息
Diabetes Metab Syndr Obes. 2021 Sep 29;14:4135-4143. doi: 10.2147/DMSO.S328206. eCollection 2021.
PURPOSE
Although fibroblast growth factor-23 (FGF23) is involved in the development of metabolic diseases, its association with metabolic-associated fatty liver disease (MAFLD) remains unknown. We explored the relationship between serum fibroblast growth factor-23 level, metabolic associated fatty liver disease, and liver fat content.
PATIENTS AND METHODS
Participants were enrolled from communities in Shanghai. Serum fibroblast growth factor-23 level was determined using two-side sandwich enzyme-linked immunosorbent assays. MAFLD was diagnosed using the international expert consensus (2020) criteria. Liver fat content was assessed using ultrasound.
RESULTS
We enrolled 1827 individuals aged 30-80 years (mean age, 59.4±7.3 years). MAFLD was diagnosed in 445/1393 (31.9%) non-diabetic participants and 245/434 (56.5%) diabetic participants. After adjusting for confounders, one standard deviation increase in serum FGF23 was associated with MAFLD in diabetic (odds ratio, 1.27; 95% confidence interval, 1.15-1.49; <0.001) and non-diabetic (odds ratio, 1.28; 95% confidence interval, 1.07-1.74; =0.030) groups. In a fully adjusted linear regression model, serum FGF23 emerged as a positive determinant of liver fat content in both diabetic and non-diabetic groups (=0.039; =0.034).
CONCLUSION
Participants with MAFLD had higher serum fibroblast growth factor-23 level than those without MAFLD, regardless of diabetes status. Serum fibroblast growth factor-23 was independently related to MAFLD and liver fat content.
目的
尽管成纤维细胞生长因子23（FGF23）参与代谢性疾病的发生发展，但其与代谢相关脂肪性肝病（MAFLD）的关系仍不清楚。我们探讨了血清成纤维细胞生长因子23水平、代谢相关脂肪性肝病和肝脏脂肪含量之间的关系。
患者和方法
研究对象来自上海社区。采用双侧夹心酶联免疫吸附测定法测定血清成纤维细胞生长因子23水平。MAFLD根据国际专家共识（2020年）标准进行诊断。使用超声评估肝脏脂肪含量。
结果
我们纳入了1827名年龄在30 - 80岁之间（平均年龄59.4±7.3岁）的个体。在1393名非糖尿病参与者中有445名（31.9%）被诊断为MAFLD，在434名糖尿病参与者中有245名（56.5%）被诊断为MAFLD。在调整混杂因素后，血清FGF23每增加一个标准差与糖尿病组（比值比，1.27；95%置信区间，1.15 - 1.49；<0.001）和非糖尿病组（比值比，1.28；95%置信区间，1.07 - 1.74；=0.030）的MAFLD相关。在一个完全调整的线性回归模型中，血清FGF23在糖尿病组和非糖尿病组中均成为肝脏脂肪含量的正性决定因素（=0.039；=0.034）。
结论
无论糖尿病状态如何，MAFLD患者的血清成纤维细胞生长因子23水平均高于无MAFLD者。血清成纤维细胞生长因子23与MAFLD和肝脏脂肪含量独立相关。
Zotero 插件